Phase 3Active, not recruiting
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (CALIBRATE)
CALIBRATE: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company (Industry)
- Enrollment
- 67 enrolled
- Conditions
- Autosomal Dominant Hypocalcemia (ADH)
- Interventions
- Encaleret; Standard of Care
- Ages
- children, adults, older adults
- Registry
- NCT05680818
Full record on ClinicalTrials.gov
From the registry
The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
Primary outcomes
- Number of Responders who Achieve Both Albumin-Corrected Blood Calcium (cCa) and 24-hour Urinary Calcium (UCa) Within the Target Range
History
Study completion expected
Last registry update
Primary completion
Registered
Started